Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer

摘要: Purpose: More than 12,000 people are expected to die from invasive transitional cell carcinoma (TCC) of the urinary bladder each year in United States, indicating that more effective therapy is needed. Drugs inhibiting cyclooxygenase (cox) have recently been found chemopreventive and antitumor activity may potentiate effects chemotherapy. The purpose this study was determine whether cisplatin combined with cox-inhibitor piroxicam would induce remission frequently alone a relevant animal model human TCC. Methods: Pet dogs naturally occurring, histopathologically confirmed, measurable TCC were randomized receive (60 mg/m2 i.v. every 21 days) or (same dosage) (0.3 mg/kg orally 24 h). Complete staging performed prior at 6-week intervals during therapy. Results: After eight had evaluated treatment group, significant difference rate noted (Fisher's Exact test, P < 0.004). Tumor responses cisplatin/piroxicam group included two complete remissions (CR), four partial (PR), stable disease (SD), no progressive (PD). CR, PR, SD, PD. Six additional treated cisplatin/piroxicam, total 10 14 (two PR). Renal toxicity frequent dose limiting. Conclusions: Cisplatin/piroxicam induced canine Strategies reduce renal need be developed evaluation humans general use pet dogs.